✦ LIBER ✦

Brain glucose metabolism in patients with mild to moderate Alzheimer's disease before and after six months treatment with intravenous immunoglobulin (octagam 10%): A phase II double blind, placebo-controlled multi-center study

✍ Scribed by Rominger, Axel; Foerster, Stefan; Zach, Christian; Dodel, Richard; Blennow, Kaj; Barkhof, Frederik; Wietek, Stefan; Haag, Stefan; Farlow, Martin; Jessen, Frank; Bartenstein, Peter

Book ID: 122467253
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 153 KB
Volume: 7
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2011.09.176

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled dose-finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%, Octapharma AG) in patients with mild to moderate Alzheimer's disease (GAM10-04)

✍ Dodel, Richard; Rominger, Axel; Blennow, Kaj; Barkhof, Frederik; Wietek, Stefan; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 87 KB

A phase 3, randomized, double-blind, pla

A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in patients with Gaucher disease type 1 (ENGAGE): Results after 9months of treatment

✍ Mistry, Pramod; Lukina, Elena; Dridi, Marie-Françoise Ben; Amato, Dominick; Bari 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 77 KB